Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophagectomy | 7 | 2022 | 447 | 0.930 |
Why?
|
Lung Neoplasms | 19 | 2023 | 12985 | 0.710 |
Why?
|
Esophageal Neoplasms | 7 | 2022 | 1575 | 0.680 |
Why?
|
Pneumonectomy | 9 | 2023 | 1091 | 0.640 |
Why?
|
Penetrance | 2 | 2014 | 381 | 0.490 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 5154 | 0.490 |
Why?
|
Burnout, Professional | 1 | 2022 | 685 | 0.450 |
Why?
|
Genes, BRCA2 | 2 | 2014 | 615 | 0.440 |
Why?
|
Genes, BRCA1 | 2 | 2014 | 779 | 0.420 |
Why?
|
Pleural Neoplasms | 3 | 2022 | 606 | 0.420 |
Why?
|
Music Therapy | 2 | 2023 | 100 | 0.390 |
Why?
|
Breast | 2 | 2017 | 1950 | 0.390 |
Why?
|
Mesothelioma | 3 | 2022 | 817 | 0.380 |
Why?
|
Neoplasms, Second Primary | 2 | 2014 | 1045 | 0.350 |
Why?
|
Heterozygote | 2 | 2014 | 2798 | 0.350 |
Why?
|
Models, Genetic | 2 | 2014 | 3493 | 0.290 |
Why?
|
Breast Neoplasms | 6 | 2017 | 20676 | 0.280 |
Why?
|
Thoracic Surgery | 2 | 2023 | 715 | 0.270 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2021 | 703 | 0.270 |
Why?
|
Neoplasms | 7 | 2023 | 21507 | 0.260 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 947 | 0.260 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2688 | 0.250 |
Why?
|
Bronchial Fistula | 1 | 2023 | 85 | 0.220 |
Why?
|
Neoplasm Staging | 13 | 2022 | 10961 | 0.220 |
Why?
|
Vaginal Diseases | 1 | 2023 | 102 | 0.220 |
Why?
|
Pleural Diseases | 1 | 2023 | 139 | 0.210 |
Why?
|
Empyema | 1 | 2021 | 41 | 0.210 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 44 | 0.200 |
Why?
|
Interneurons | 2 | 2016 | 577 | 0.200 |
Why?
|
Thymoma | 1 | 2022 | 186 | 0.190 |
Why?
|
Lymphatic Metastasis | 4 | 2021 | 2897 | 0.190 |
Why?
|
Carcinoma, Large Cell | 1 | 2021 | 113 | 0.190 |
Why?
|
Precancerous Conditions | 3 | 2017 | 966 | 0.190 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2023 | 357 | 0.180 |
Why?
|
Thoracic Neoplasms | 1 | 2022 | 267 | 0.180 |
Why?
|
Thymus Neoplasms | 1 | 2022 | 268 | 0.180 |
Why?
|
Keratins | 1 | 2021 | 516 | 0.180 |
Why?
|
Palliative Care | 3 | 2023 | 3461 | 0.180 |
Why?
|
Gastrostomy | 1 | 2022 | 307 | 0.170 |
Why?
|
Thoracic Surgical Procedures | 1 | 2023 | 342 | 0.170 |
Why?
|
Morals | 1 | 2022 | 287 | 0.170 |
Why?
|
Bereavement | 1 | 2023 | 273 | 0.170 |
Why?
|
Retrospective Studies | 24 | 2022 | 76631 | 0.170 |
Why?
|
Pneumothorax | 1 | 2022 | 379 | 0.170 |
Why?
|
Hyperplasia | 3 | 2017 | 1181 | 0.170 |
Why?
|
Chlamydia trachomatis | 1 | 2019 | 246 | 0.150 |
Why?
|
Learning Curve | 1 | 2018 | 200 | 0.150 |
Why?
|
Humans | 59 | 2023 | 739398 | 0.150 |
Why?
|
Gastrectomy | 1 | 2021 | 642 | 0.150 |
Why?
|
Ependymoma | 1 | 2020 | 333 | 0.150 |
Why?
|
raf Kinases | 1 | 2017 | 122 | 0.150 |
Why?
|
Hospices | 1 | 2020 | 264 | 0.140 |
Why?
|
Contact Tracing | 1 | 2019 | 273 | 0.140 |
Why?
|
Organ Culture Techniques | 2 | 2015 | 813 | 0.140 |
Why?
|
Hydrocarbons | 1 | 2016 | 100 | 0.140 |
Why?
|
Preoptic Area | 1 | 2016 | 147 | 0.130 |
Why?
|
Chlamydia Infections | 1 | 2019 | 364 | 0.130 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2017 | 217 | 0.130 |
Why?
|
Astrocytoma | 2 | 2017 | 789 | 0.130 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 722 | 0.130 |
Why?
|
Aged | 22 | 2023 | 162698 | 0.130 |
Why?
|
Telencephalon | 1 | 2015 | 144 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1116 | 0.130 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2021 | 643 | 0.120 |
Why?
|
Drug Hypersensitivity | 1 | 2023 | 889 | 0.120 |
Why?
|
Carcinoma, Lobular | 2 | 2015 | 482 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6516 | 0.120 |
Why?
|
Adenocarcinoma | 2 | 2021 | 6318 | 0.110 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 554 | 0.110 |
Why?
|
Hospice Care | 1 | 2020 | 671 | 0.110 |
Why?
|
Frail Elderly | 3 | 2023 | 690 | 0.110 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2021 | 981 | 0.110 |
Why?
|
Stress, Psychological | 3 | 2023 | 4212 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2021 | 9122 | 0.110 |
Why?
|
Decision Support Systems, Clinical | 1 | 2021 | 1162 | 0.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11410 | 0.110 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 1994 | 0.100 |
Why?
|
Protein Multimerization | 1 | 2017 | 970 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.100 |
Why?
|
Prognosis | 8 | 2021 | 28901 | 0.100 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 894 | 0.100 |
Why?
|
Coculture Techniques | 1 | 2015 | 1343 | 0.100 |
Why?
|
Calibration | 1 | 2014 | 818 | 0.100 |
Why?
|
Survival Rate | 6 | 2021 | 12761 | 0.100 |
Why?
|
Neural Inhibition | 1 | 2015 | 595 | 0.100 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2409 | 0.100 |
Why?
|
Mammary Glands, Human | 1 | 2012 | 200 | 0.100 |
Why?
|
Postoperative Complications | 6 | 2022 | 15194 | 0.100 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 250 | 0.100 |
Why?
|
Female | 25 | 2023 | 378853 | 0.100 |
Why?
|
Decision Support Techniques | 1 | 2021 | 1957 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2022 | 2067 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 1100 | 0.090 |
Why?
|
Geriatric Assessment | 3 | 2023 | 1366 | 0.090 |
Why?
|
Chemoprevention | 1 | 2012 | 323 | 0.090 |
Why?
|
Treatment Outcome | 12 | 2022 | 62693 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1888 | 0.090 |
Why?
|
Heart Diseases | 1 | 2023 | 2782 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2141 | 0.090 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 514 | 0.090 |
Why?
|
Parents | 4 | 2023 | 3368 | 0.090 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 799 | 0.090 |
Why?
|
Critical Illness | 1 | 2022 | 2656 | 0.090 |
Why?
|
Decision Making | 1 | 2023 | 3854 | 0.090 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2015 | 3485 | 0.090 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 1574 | 0.080 |
Why?
|
Lung | 3 | 2022 | 9782 | 0.080 |
Why?
|
Neural Stem Cells | 1 | 2015 | 843 | 0.080 |
Why?
|
HIV Antibodies | 1 | 2015 | 1309 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13635 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1054 | 0.080 |
Why?
|
Middle Aged | 15 | 2022 | 212863 | 0.080 |
Why?
|
SEER Program | 1 | 2012 | 1506 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 1602 | 0.070 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2017 | 2015 | 0.070 |
Why?
|
Aged, 80 and over | 7 | 2022 | 57650 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3650 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4640 | 0.070 |
Why?
|
Tumor Microenvironment | 2 | 2015 | 3508 | 0.070 |
Why?
|
Mass Screening | 2 | 2019 | 5265 | 0.070 |
Why?
|
Fibroblasts | 1 | 2016 | 4137 | 0.070 |
Why?
|
Child | 9 | 2023 | 77033 | 0.070 |
Why?
|
Adult | 13 | 2021 | 213394 | 0.070 |
Why?
|
Young Adult | 8 | 2023 | 56255 | 0.070 |
Why?
|
Antibodies, Neutralizing | 1 | 2015 | 1957 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4014 | 0.070 |
Why?
|
Brain Neoplasms | 2 | 2017 | 8791 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1373 | 0.060 |
Why?
|
Paclitaxel | 2 | 2023 | 1701 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 24714 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2012 | 2303 | 0.060 |
Why?
|
Male | 18 | 2023 | 349022 | 0.060 |
Why?
|
Age Factors | 2 | 2021 | 18349 | 0.060 |
Why?
|
Peptides | 1 | 2016 | 4395 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2017 | 17384 | 0.060 |
Why?
|
Nerve Net | 1 | 2015 | 2179 | 0.060 |
Why?
|
Cell Movement | 1 | 2015 | 5221 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2694 | 0.060 |
Why?
|
Clinical Competence | 1 | 2018 | 4671 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3453 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2015 | 2971 | 0.050 |
Why?
|
Risk Assessment | 3 | 2021 | 23294 | 0.050 |
Why?
|
Thymectomy | 1 | 2022 | 192 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2021 | 5058 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 110 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 6310 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6871 | 0.050 |
Why?
|
Transcription Factors | 1 | 2021 | 12120 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5502 | 0.050 |
Why?
|
Grief | 1 | 2023 | 247 | 0.050 |
Why?
|
Attitude to Death | 1 | 2023 | 381 | 0.050 |
Why?
|
Risk | 1 | 2012 | 9684 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2021 | 38942 | 0.050 |
Why?
|
Risk Factors | 7 | 2022 | 71974 | 0.050 |
Why?
|
Taxoids | 1 | 2023 | 661 | 0.040 |
Why?
|
Epinephrine | 1 | 2023 | 795 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2021 | 3454 | 0.040 |
Why?
|
Hospitalization | 1 | 2019 | 10208 | 0.040 |
Why?
|
HIV Infections | 2 | 2016 | 16764 | 0.040 |
Why?
|
Remission Induction | 2 | 2015 | 2378 | 0.040 |
Why?
|
Mutation | 2 | 2014 | 29658 | 0.040 |
Why?
|
Polypharmacy | 1 | 2021 | 290 | 0.040 |
Why?
|
Indocyanine Green | 1 | 2020 | 239 | 0.040 |
Why?
|
Death | 1 | 2023 | 670 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 194 | 0.040 |
Why?
|
Tracheostomy | 1 | 2022 | 402 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 564 | 0.040 |
Why?
|
Length of Stay | 2 | 2022 | 6295 | 0.040 |
Why?
|
Anxiety | 2 | 2023 | 4253 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 800 | 0.040 |
Why?
|
Infant, Low Birth Weight | 1 | 2022 | 848 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2021 | 270 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9846 | 0.040 |
Why?
|
Time Factors | 4 | 2021 | 40050 | 0.040 |
Why?
|
HIV-1 | 1 | 2015 | 6931 | 0.040 |
Why?
|
Anastomotic Leak | 1 | 2018 | 162 | 0.040 |
Why?
|
Tumor Burden | 1 | 2023 | 1904 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 928 | 0.040 |
Why?
|
Adolescent | 5 | 2023 | 85405 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12328 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 970 | 0.030 |
Why?
|
Caribbean Region | 1 | 2016 | 194 | 0.030 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2022 | 773 | 0.030 |
Why?
|
Naphthalimides | 1 | 2015 | 21 | 0.030 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 3051 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
Daunorubicin | 1 | 2015 | 150 | 0.030 |
Why?
|
Surgical Flaps | 1 | 2023 | 1627 | 0.030 |
Why?
|
Survival Analysis | 2 | 2020 | 10247 | 0.030 |
Why?
|
United States | 5 | 2022 | 69573 | 0.030 |
Why?
|
Sexual Partners | 1 | 2019 | 727 | 0.030 |
Why?
|
Prospective Studies | 4 | 2023 | 53037 | 0.030 |
Why?
|
Prosencephalon | 1 | 2016 | 304 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2020 | 1242 | 0.030 |
Why?
|
Automation, Laboratory | 1 | 2014 | 99 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2872 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1524 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 192 | 0.030 |
Why?
|
Mexico | 1 | 2016 | 683 | 0.030 |
Why?
|
Dyspnea | 1 | 2021 | 1295 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2023 | 2040 | 0.030 |
Why?
|
Intention | 1 | 2016 | 337 | 0.030 |
Why?
|
Cytarabine | 1 | 2015 | 685 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 552 | 0.030 |
Why?
|
Microspheres | 1 | 2015 | 778 | 0.030 |
Why?
|
Mothers | 1 | 2023 | 2143 | 0.030 |
Why?
|
Vincristine | 1 | 2014 | 1038 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2015 | 916 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2019 | 1645 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 380 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 694 | 0.020 |
Why?
|
Emotions | 1 | 2023 | 2642 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 953 | 0.020 |
Why?
|
Androstadienes | 1 | 2012 | 340 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2017 | 1015 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3524 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3514 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2679 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2016 | 616 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2261 | 0.020 |
Why?
|
Quality of Life | 2 | 2021 | 12640 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2270 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1560 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 2092 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1374 | 0.020 |
Why?
|
Adenine | 1 | 2015 | 940 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3286 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2711 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2015 | 1698 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1786 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3562 | 0.020 |
Why?
|
Mice | 4 | 2017 | 81002 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3606 | 0.020 |
Why?
|
Boston | 1 | 2022 | 9314 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4192 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2238 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8275 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8605 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 2704 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2218 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2022 | 7726 | 0.020 |
Why?
|
Tamoxifen | 1 | 2012 | 978 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2015 | 1925 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 13872 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8669 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9133 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3603 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4935 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 7897 | 0.020 |
Why?
|
Pain | 1 | 2021 | 4923 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2486 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4182 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 9812 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2014 | 2440 | 0.020 |
Why?
|
Smoking | 1 | 2022 | 8960 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2021 | 13880 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 8400 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2020 | 4365 | 0.020 |
Why?
|
Patient Readmission | 1 | 2018 | 3106 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10455 | 0.020 |
Why?
|
Genomics | 1 | 2020 | 5652 | 0.020 |
Why?
|
Mammography | 1 | 2015 | 2466 | 0.020 |
Why?
|
Animals | 4 | 2017 | 168368 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7274 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2014 | 3007 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 3433 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15511 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8274 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2020 | 11460 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4239 | 0.010 |
Why?
|
Physicians | 1 | 2021 | 4539 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2015 | 4463 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4555 | 0.010 |
Why?
|
Medicare | 1 | 2020 | 6497 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25470 | 0.010 |
Why?
|
Models, Statistical | 1 | 2017 | 5113 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15153 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7788 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11347 | 0.010 |
Why?
|
Neurons | 1 | 2020 | 9336 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12237 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 40389 | 0.010 |
Why?
|
Infant | 1 | 2022 | 34923 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5830 | 0.010 |
Why?
|
Depression | 1 | 2019 | 7689 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 19220 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20055 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6570 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2015 | 5721 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9387 | 0.010 |
Why?
|